Company news

VYNE Therapeutics Inc. news in 2024

VYNE Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

December 22, 2024

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

September 11, 2024

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

July 15, 2024

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

July 8, 2024

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

June 12, 2024

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

June 4, 2024

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 5, 2024

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

April 30, 2024

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

February 28, 2024

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

January 9, 2024

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

January 2, 2024

Decks in 2024